Protocol Ledger

NCT05710328 · Phase II · ACTIVE NOT RECRUITING

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Interventional Phase II clinical trial protocol NCT05710328 sponsored by ECOG-ACRIN Cancer Research Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-05-10 Enrollment: 235 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05710328
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)235 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05710328
Protocol FieldVerified Registry Value
NCT IdentifierNCT05710328
Consolidated Lead SponsorECOG-ACRIN Cancer Research Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment235 participants (ESTIMATED)
Registered Start Date2023-05-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI